Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis

Kathryn L. Pepple, Phoebe Lin

Research output: Contribution to journalReview article

7 Scopus citations

Abstract

The interleukin (IL)-23/IL-17 axis plays a central role in the pathogenesis of immune-mediated diseases such as psoriasis, psoriatic arthritis, Crohn's disease, and uveitis. Therefore, targeting the IL-23/IL-17 axis has become the focus of multiple clinical trials for drug development in patients with autoimmune diseases. We briefly describe the biology of the IL-23/IL-17 axis and its relevance to the pathogenesis of experimental and clinical uveitis, and review the monoclonal antibody therapies targeting this pathway. Finally, 2 ongoing phase 2 trials of the anti–IL-23 biologic therapy ustekinumab (STELARA, Janssen Biotech Inc, Horsham, PA) in patients with noninfectious uveitis are introduced.

Original languageEnglish (US)
Pages (from-to)1977-1983
Number of pages7
JournalOphthalmology
Volume125
Issue number12
DOIs
Publication statusPublished - Dec 1 2018

    Fingerprint

Cite this